Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4801-4809

  Wang, Yan ^a   Gu, Jian ^a   Roth, Jack A ^a   Hildebrandt, Michelle A T ^a   Lippman, Scott M ^c   Ye, Yuanqing ^a   Minna, John D ^b   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; MICRORNA 106A; MICRORNA 106B; MICRORNA 145; MICRORNA 148A; MICRORNA 148B; MICRORNA 152; MICRORNA 16; MICRORNA 20A; MICRORNA 26A; MICRORNA 27A; MICRORNA 27B; MICRORNA 301A; MICRORNA 30A 5P; MICRORNA 30E 3P; MICRORNA 92A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; ARTICLE; BINDING SITE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DEATH; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL TIME;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881398405     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3273     Document Type: Article

References (49)

1. American Cancer Society: Cancer facts and figures. Atlanta, GA, American Cancer Society, 2012.
2. Esteban E, Casillas M, Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009;35:364-73
3. Gebbia V. Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer? Expert Opin Pharmacother 2008;9: 1321-37.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced nonsmall- cell lung cancer. New Engl J Med 2002;346:92-8.
5. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
6. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
7. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-8.
8. Calin G, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8.
10. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
11. Chen X, Ba Y, Ma LJ, Cai X, Yin Y, Wang KH, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
12. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
13. Mitchell P, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova- Agadjanyan EL, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008;105: 10513-18.
14. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as noninvasive biomarkers for cancer. Mol Cancer 2010;9:306.
15. Massague J. TGF beta in cancer. Cell 2008;134:215-30.
16. Meulmeester E, ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol 2011;223:205-18.
17. Lin MB, Stewart DJ, Spitz MR, Hildebrandt MAT, Lu C, Lin J, et al. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 2011;32:1050-6.
18. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are micro- RNA targets. Cell 2005;120:15-20.
19. Friedman RC, Farh KKH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105.
20. Livak K, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DeltaDelta C(T)) method. Methods 2001;25:402-8.
21. Liu HS, Zhu L, Liu BY, Yang L, Meng XX, Zhang W, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012;316:196-203.
22. Zhou XH, Obuchowski N, McClish D. Thoughts on the ZOM/BWC controversy-replies. Acad Radiol 2003;10:1179-80.
23. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
24. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
25. Lin QF, Mao WD, Shu YQ, Lin F, Liu SP, Shen H, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin 2012;138:85-93.
26. Roybal JD, Zang Y, Ahn YH, Yang YN, Gibbons DL, Baird BN, et al. miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res 2011;9:25-35.
27. Hu ZB, Chen X, Zhao Y, Tian T, Jin GF, Shu YQ, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6.
28. National Cancer Institute. Non-small cell lung cancer treatment (PDQ)- Health professional version. National Cancer Institute (http://www. cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/ healthprofessional). Accessed May 2013.
29. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011;6:482-8.
30. Silva J, Garcia V, Zaballos A, Provencio M, Lombardia L, Almonacid L, et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011; 37:617-23.
31. Zhang CN, Wang C, Chen X, Yang CH, Li K, Wang JJ, et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010;56:1871-9.
32. Zhang TF, Wang QM, Zhao D, Cui YL, Cao BR, Guo LP, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci 2011;121: 437-47.
33. Wang TT, Lv MM, Shen SN, Zhou S, Wang P, Chen YQ, et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS ONE 2012;7: e43268.
34. Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 2011;104:847-51.
35. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in preand post-operative lung carcinoma patients. Med Oncol 2012;29: 3190-7.
36. Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T, et al. Reduction of plasma microRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chinese J Cancer Res 2011;23:123-8.
37. Zheng DL, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-86.
38. Ma YX, Tian ZN, Zhang W. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin 2012;138:2045-50.
39. Wu J, Yang T, Li X, Yang Q, Liu R, Huang J, et al. Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Toxicol Appl Pharmacol 2013;18:002.
40. Navarro A, Diaz T, Gallardo E, Vinolas N, Marrades RM, Gel B, et al. Prognostic implications of miR-16 expression levels in resected nonsmall- cell lung cancer. J Surg Oncol 2011;103:411-5.
41. Castillejo A, Rothman N, Murta-Nascimento C, Malats N, Garcia- Closas M, Gomez-Martinez A, et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 2009;124:608-13.
42. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011;57:833-40.
43. Novitskiy SV, PickupMW,Gorska AE, OwensP, Chytil A, Aakre M, et al. TGF-beta receptor II loss promotes mammary carcinoma progression by Th17-dependent mechanisms. Cancer Discov 2011;1:430-41.
44. Raynal S,Nocentini S, Croisy A, Lawrence DA, Jullien P. Transforming growth factor-beta 1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 1997; 72:356-61.
45. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 2006;13: 849-51.
46. Jeon HS, Jen J. TGF-beta signaling and the role of inhibitory smads in non-small cell lung cancer. J Thorac Oncol 2010;5:417-9.
47. Masui T, Wakefield LM, Lechner JF, Laveck MA, Sporn MB, Harris CC. Type-Beta transforming growth-factor is the primary differentiationinducing serum factor for normal human bronchial epithelial-cells. Proc Natl Acad Sci USA 1986;83:2438-42.
48. Masui T, Wakefield LM, Lechner JF, Laveck MA, Gerwin BI, Sporn MB, et al. Type-Beta transforming growth-factor induction of squamous differentiation of normal human bronchial epithelial-cells is antagonized by epinephrine and cholera-toxin. J Cell Biochem 1986;10C:118.
49. Liu R, Zhang CN, Hu ZB, Li G,WangC, Yang CH, et al.Afive-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011;47:784-91.